外周血管介入术后对比剂相关急性肾损伤的危险因素与安全对比剂容量阈值
该研究基于血管质量倡议(VQI)数据库2010-2018年53,780例外周血管介入(PVI)手术,分析对比剂相关急性肾损伤(PC-AKI)的发生率、危险因素及安全对比剂容量阈值。结果显示PC-AKI总体发生率为0.9%,且随慢性肾脏病(CKD)分期增加而升高;晚期CKD的安全阈值分别为CKD3 50 mL、CKD4 20 mL、CKD5 9 mL。发生PC-AKI的患者院内死亡率和长期生存率均更差。
要点
- PC-AKI总体发生率0.9%,CKD3-5期分别为1.5%、4.3%、7.5%。
- 晚期CKD安全对比剂容量阈值:CKD3 50 mL、CKD4 20 mL、CKD5 9 mL。
- 住院状态、糖尿病、晚期CKD、严重肢体缺血等显著增加PC-AKI风险。
核心结论
- PVI术后PC-AKI风险总体较低,但晚期CKD患者接受高急症手术时风险显著升高。
- PC-AKI与短期和长期死亡率强相关,应通过安全对比剂容量阈值最小化风险。
研究设计与样本
- 回顾性队列研究,基于Vascular Quality Initiative(VQI)数据库2010-2018年PVI记录。
- 排除透析、肾移植或发生出血并发症的患者,仅纳入基线肌酐、对比剂容量和PC-AKI数据完整的记录。
- 共纳入53,780例手术,PC-AKI定义为肌酐升高≥0.5 mg/dL或需要新透析。
主要发现
- PC-AKI总体发生率为0.9%,各CKD分期发生率:正常/CKD1 0.39%、CKD2 0.45%、CKD3 1.5%、CKD4 4.3%、CKD5 7.5%。
- 晚期CKD安全对比剂容量阈值(PC-AKI累积发生率≤0.5%):CKD3 50 mL、CKD4 20 mL、CKD5 9 mL。
- 多变量回归显示住院状态(OR 14.5,95%CI 9.97-21.2)、糖尿病(OR 1.27,95%CI 1.02-1.58)、CKD3(OR 3.65,95%CI 2.68-4.98)、CKD4(OR 6.98,95%CI 4.72-10.3)、CKD5(OR 8.94,95%CI 4.53-17.6)、严重肢体缺血(OR 1.51,95%CI 1.14-2.00)、急性肢体缺血(OR 2.47,95%CI 1.70-3.59)及对比剂与eGFR比值(CGR)升高与PC-AKI风险增加相关。
- 白色人种(OR 0.67,95%CI 0.54-0.82)和择期手术(OR 0.77,95%CI 0.62-0.95)与PC-AKI风险降低相关。
- 发生PC-AKI的患者院内死亡率更高(16.1% vs 0.45%,P < .01),长期生存更差(log-rank P < .01)。
关键数值与推荐
- PC-AKI定义:肌酐升高≥0.5 mg/dL或需要新透析。
- 安全对比剂容量阈值定义为PC-AKI累积发生率≤0.5%时的对比剂容量。
- 晚期CKD安全阈值:CKD3 50 mL、CKD4 20 mL、CKD5 9 mL。
临床怎么用
- 对晚期CKD患者行PVI时,应参考CKD3 50 mL、CKD4 20 mL、CKD5 9 mL的对比剂容量阈值以降低PC-AKI风险。
- 对住院、糖尿病、严重/急性肢体缺血等高危患者应加强术后肾功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Postcontrast acute kidney injury (PC-AKI) is a dreaded complication of peripheral vascular interventions (PVIs) that depends on the volume of contrast administered as well as a patient's baseline kidney function. However, there is currently no guidance on the volume of contrast that is considered safe especially for patients with advanced chronic kidney disease (CKD). This study aims to characterize the incidence, risk factors for, and outcomes after PC-AKI and define thresholds of safety for contrast volume. METHODS: The Vascular Quality Initiative files for PVI (2010-2018) were reviewed. Patients on dialysis, with renal transplants, or who developed a bleeding complication were excluded. Only records with complete data on baseline creatinine, contrast volume, and PC-AKI (creatinine increase of ≥0.5 mg/dL, or new dialysis requirement) were included. The cumulative incidence of PC-AKI with contrast volume at each stage of CKD was derived. A safe threshold for contrast volume was defined as the volume at which the cumulative incidence of PC-AKI is 0.5% or less. Multivariable logistic regression was used to define risk factors for PC-AKI, and survival analysis was performed using Kaplan-Meier and multivariable Cox proportional hazards regression. RESULTS: A total of 53,780 procedures were included. There were 16,062 patients (29%) with normal kidney function or CKD1, 21,769 (39%) with CKD2, 14,234 (25%) with CKD3, 1471 (3%) with CKD4, and 199 (<1%) with CKD5. The incidence of PC-AKI was 0.9% and increased with each stage of CKD (CKD1, 0.39%; CKD2, 0.45%; CKD3, 1.5%; CKD4, 4.3%; and CKD5, 7.5%). The safe thresholds for contrast volume for advanced CKD were 50, 20, and 9 mL for CKD3, CKD4, and CKD5, respectively. Regression analysis demonstrated that white race (odds ratio [OR], 0.67; 95% confidence interval [CI], 0.54-0.82) and elective surgery (OR, 0.77; 95% CI, 0.62-0.95) were associated with decreased risk of PC-AKI, whereas inpatient status (OR, 14.5; 95% CI, 9.97-21.2), diabetes (OR, 1.27; 95% CI, 1.02-1.58), advanced CKD (CKD3: OR, 3.65; 95% CI, 2.68-4.98; CKD4: OR, 6.98; 95% CI, 4.72-10.3; CKD5: OR, 8.94; 95% CI, 4.53-17.6), critical limb ischemia (OR, 1.51; 95% CI, 1.14-2.00), acute limb ischemia (OR, 2.47; 95% CI, 1.70-3.59), and contrast-to-eGFR ratio (CGR) (2 ≤ CGR < 3: OR, 1.33; 95% CI, 1.02-1.74; 3 ≤ CGR < 4: OR, 1.90; 95% CI, 1.32-2.75; CGR ≥ 4: OR, 1.79; 95% CI, 1.18-2.70) were significantly associated with increased risk for PC-AKI. Patients who developed PC-AKI had worse in-hospital (16.1% vs 0.45%; P < .01) mortality and long-term survival (log-rank P < .01) compared with those without PC-AKI. CONCLUSIONS: PVI are associated with low risk of PC-AKI that significantly increases when patients with advanced CKD undergo high acuity cases. Given the strong association with short-term and long-term mortality, risk of PC-AKI should be minimized by using safe thresholds of contrast volume.
引用
- Lee SR, Zhuo H, Zhang Y, et al. Risk factors and safe contrast volume thresholds for postcontrast acute kidney injury after peripheral vascular interventions. J Vasc Surg. 2019. PMID: 31843298. doi:10.1016/j.jvs.2019.09.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。